Hee-mok Won, chairman of the Korea Pharmaceutical Bio Association, succeeded in extending his term, and he will serve as the chairman for two more years until February 2023.
On the afternoon of the 19th, the presidency of the association held the first meeting in 2021 and unanimously decided to extend the term of office for the current chairman Hee-mok Won.
According to the Articles of Incorporation (Article 13), a president who has a two-year term of office may be reappointed once, and only the president who has been reappointed can be extended one term by a special resolution of the chairman and directors if necessary. Chairman Won took office as the 21st president in February 2017, and reappointed as president for two years in February 2019.
On this day, the chairman and director said, “In the corona 19 pandemic, considering the national expectations of the pharmaceutical bio industry and the challenges of the times, Chairman Won, who has been leading the association, is the best person to derive tangible results from the establishment of the foundation for global success and pharmaceutical sovereignty in our industry. He said, “Unanimously, I decided to ask President Won for two more years of hard work.”
Accordingly, Chairman Won said, “I would like to express my special gratitude to the member companies and executives and employees of the association who are doing their best to develop the industry and overcome Corona 19. We will feel and work together to carry out the given task.”
He added, “We will focus on solidifying the various public-private partnerships and industrial innovation projects we have been pursuing so far more solidly to systematize and to maximize synergy in a virtuous cycle and organically.”
Immediately after taking office in 2017, Chairman Won named’the pharmaceutical industry is a logistics base for health and security and a food for the future’, and secured growth engines along with topics such as’The only way to live by R&D investment’ and’Ethical management is the trend’. They demanded bold industrial support from the government.
In addition, ISO 37001 (Anti-Corruption Management System) in line with international standards was introduced to promote the participation of member companies to establish ethical management and enhance market transparency.
Last year, the Korea Innovative Medicines Consortium (KIMCo) was launched for the first time in a joint venture with the association and member companies to support joint responses to infectious diseases and the development of innovative new drugs.
In addition, tangible results were achieved in entering the global advanced markets and revitalizing technology exchange by entering the Cambridge Innovation Center (CIC) in the U.S. and joining the Consortium of the Massachusetts Institute of Technology (MIT) Industry-Academic Partnership Program (ILP) in the U.S.
Meanwhile, Chairman Won, a graduate of Seoul National University Pharmacy University, has served as the president of the Korean Pharmaceutical Association (the 33rd and 34th), the 18th National Assembly member (the National Assembly Health and Welfare Committee), and the Director of the Social Security Intelligence Agency.